Clinical Trials Directory

Trials / Completed

CompletedNCT03196804

A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.

A Dose Blocked-randomized, Double-blind, Placebo-controlled, Multiple Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
LG Chem · Industry
Sex
Male
Age
19 Years – 45 Years
Healthy volunteers
Accepted

Summary

To assess the safety, tolerability and pharmacokinetic characteristics of LC-28-0126 multiple iv injection in healthy male subjects.

Conditions

Interventions

TypeNameDescription
DRUGLC28-0126LC28-0126
DRUGPlaceboPlacebo

Timeline

Start date
2017-06-07
Primary completion
2017-11-15
Completion
2017-11-15
First posted
2017-06-23
Last updated
2018-04-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03196804. Inclusion in this directory is not an endorsement.

A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126. (NCT03196804) · Clinical Trials Directory